US-based BioVentrix has announced that placement of its Revivent-TC ventricular enhancement system, via Less Invasive Ventricular Enhancement (LIVE) procedure, has been successfully expanded to a second European clinical site. The ...
CardioKinetix has completed enrolling the first patient in PARACHUTE IV trial of its Parachute ventricular partitioning device for treating heart failure patients. The minimally invasive device is deployed into the left ventricle to ...
CardioKinetix has started enrolling patients for its PARACHUTE III, a post-market safety surveillance trial, in Germany. The dual-arm, multi-center, open-label trial, which will enroll up to 100 ischemic heart failure patients, is ...
CardioKinetix has obtained CE mark approval for its full size matrix of its percutaneous ventricular restoration device to treat patients with ischemic heart failure. The Parachute ventricular partitioning device uses a small catheter ...
Tags: CE Mark, heart failure, medical device